Claims for Patent: 11,020,407

Summary for Patent: 11,020,407

Title:	Corticosteroid containing foam compositions and method of manufacture thereof
Abstract:	The present invention provides a method for treating various skin diseases by topically administering to a subject a composition formulated as a foamable composition which includes a corticosteroid, such as halobetasol. The composition may include a corticosteroid, ethyl alcohol, emulsifying wax, cetostearyl alcohol, polyoxyl 20 cetostearyl ether, water, benzoic acid and propellant.
Inventor(s):	Gauthier; Robert T. (San Diego, CA), Hammer; James D. (Uxbridge, MA)
Assignee:	MAYNE PHARMA LLC (Greenville, NC)
Application Number:	15/365,152
Patent Claims:	1. A method for treating a skin disease, condition or disorder in a subject, the method comprising topically administering to the subject a composition, the composition comprising, on a weight basis: a) 0.02 to 0.10% halobetasol or its pharmaceutically acceptable salts, esters, and solvates; b) 40 to 60% ethyl alcohol; c) 0.1 to 5.0% Emulsifying Wax, NF; d) 0.05 to 1.0% cetostearyl alcohol; e) 0.05 to 1.0% polyoxyl 20 cetostearyl ether; f) 1 to 10% propylene glycol; g) 30 to 40% water; h) greater than 0.0% and less than 0.0005% benzoic acid; and i) 3.25 to 5.75% propellant, wherein the composition has a pH of between about 4.0 to 6.3, wherein the composition is void of a buffer system. 2. The method of claim 1, wherein the skin disease, condition or disorder is selected from the group consisting of allergic contact dermatitis, eczema, asteatotic eczema, discoid eczema, infantile eczema, diaper dermatitis, psoriasis; plaque psoriasis, palmoplantar psoriasis, seborrheic dermatitis, atopic dermatitis, dermatitis herpetiformis, neurodermatitis, lichen simplex chronicus, lichen planus, subacute cutaneous lupus erythematosus, urticaria, discoid lupus erythematosus, chronic hypertrophic lichen planus, granuloma annulare, keloid scars, reactions to insect and spider bites, Pityriasis rosea, erythema, and pruritis. 3. The method of claim 1, wherein the subject is a human. 4. The method of claim 1, wherein the composition is administered once daily, twice daily, weekly, biweekly, or monthly. 5. The method of claim 1, wherein the administration does not decrease transepidermal water loss (TEWL) at the treated administration site. 6. The method of claim 1, wherein the administration does not increase skin hydration at the treated administration site. 7. The method of claim 1, wherein the administration does not decrease transepidermal water loss (TEWL) at the treated administration site and does not increase skin hydration at the treated administration site. 8. The method of claim 1, wherein the skin disease, condition or disorder is psoriasis. 9. The method of claim 2, wherein the skin disease, condition or disorder is plaque psoriasis. 10. The method of claim 4, wherein the composition is administered once daily. 11. The method of claim 4, wherein the composition is administered twice daily.